Cannabinoids in Parkinson's Disease

The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the...

Descripción completa

Detalles Bibliográficos
Autores principales: Stampanoni Bassi, Mario, Sancesario, Andrea, Morace, Roberta, Centonze, Diego, Iezzi, Ennio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436333/
https://www.ncbi.nlm.nih.gov/pubmed/28861502
http://dx.doi.org/10.1089/can.2017.0002
_version_ 1783237379792830464
author Stampanoni Bassi, Mario
Sancesario, Andrea
Morace, Roberta
Centonze, Diego
Iezzi, Ennio
author_facet Stampanoni Bassi, Mario
Sancesario, Andrea
Morace, Roberta
Centonze, Diego
Iezzi, Ennio
author_sort Stampanoni Bassi, Mario
collection PubMed
description The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies.
format Online
Article
Text
id pubmed-5436333
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-54363332017-08-31 Cannabinoids in Parkinson's Disease Stampanoni Bassi, Mario Sancesario, Andrea Morace, Roberta Centonze, Diego Iezzi, Ennio Cannabis Cannabinoid Res Mini-Review The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies. Mary Ann Liebert, Inc. 2017-02-01 /pmc/articles/PMC5436333/ /pubmed/28861502 http://dx.doi.org/10.1089/can.2017.0002 Text en © Mario Stampanoni Bassi et al. 2017; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Mini-Review
Stampanoni Bassi, Mario
Sancesario, Andrea
Morace, Roberta
Centonze, Diego
Iezzi, Ennio
Cannabinoids in Parkinson's Disease
title Cannabinoids in Parkinson's Disease
title_full Cannabinoids in Parkinson's Disease
title_fullStr Cannabinoids in Parkinson's Disease
title_full_unstemmed Cannabinoids in Parkinson's Disease
title_short Cannabinoids in Parkinson's Disease
title_sort cannabinoids in parkinson's disease
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436333/
https://www.ncbi.nlm.nih.gov/pubmed/28861502
http://dx.doi.org/10.1089/can.2017.0002
work_keys_str_mv AT stampanonibassimario cannabinoidsinparkinsonsdisease
AT sancesarioandrea cannabinoidsinparkinsonsdisease
AT moraceroberta cannabinoidsinparkinsonsdisease
AT centonzediego cannabinoidsinparkinsonsdisease
AT iezziennio cannabinoidsinparkinsonsdisease